As cell and gene therapies expand across therapeutic areas, health systems are managing complex workflows involving prior authorizations, care coordination, reimbursement, manufacturer requirements, and operational logistics. Longitude CGT is being developed to provide technology-enabled tools and operational capabilities that help teams coordinate work more efficiently, improve visibility across the patient journey, and support scalable delivery of advanced therapies.

“Cell and gene therapy represents one of the most promising areas of medicine, but it also creates significant operational and financial complexity for health systems,” said Sinthu Sinnadurai, president of Longitude CGT, in a statement. “The active participation of all five Longitude Health member systems will help us build solutions grounded in the realities of care delivery. Our goal is to reduce administrative burden and improve access for patients who need these therapies.”

The health systems will help validate workflows, identify opportunities for operational improvement, and inform the development of a scalable technology platform and services model. Their experience spans academic medical centers, specialty hospitals, children’s hospitals, and large integrated delivery networks.

“As a development partner, Michigan Medicine is helping shape Longitude CGT around real patient cases and the practical needs of health systems delivering these therapies,” said Dana Habers, chief innovations officer and chief operating officer, pharmacy, Michigan Medicine, in a statement. “Grounding this work in real-world experience is essential to building solutions that strengthen care coordination and enhance patient access.”